Serum Concentration-Dependent Inhibition of CYP2D6 by Bupropion and Doxepin: Implications for Venlafaxine and Risperidone Metabolism.

Zioris GN, Warrings B, Deckert J, Walther S, Unterecker S, Scherf-Clavel M

Open source

DOI
10.1055/a-2812-9208
Published
2026 Mar 2
Container
Pharmacopsychiatry
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1055/a-2812-9208,
  title = {Serum Concentration-Dependent Inhibition of CYP2D6 by Bupropion and Doxepin: Implications for Venlafaxine and Risperidone Metabolism.},
  author = {Zioris GN and Warrings B and Deckert J and Walther S and Unterecker S and Scherf-Clavel M},
  year = {2026},
  journal = {Pharmacopsychiatry},
  doi = {10.1055/a-2812-9208},
  url = {https://doi.org/10.1055/a-2812-9208}
}

RIS

TY  - JOUR
TI  - Serum Concentration-Dependent Inhibition of CYP2D6 by Bupropion and Doxepin: Implications for Venlafaxine and Risperidone Metabolism.
AU  - Zioris GN
AU  - Warrings B
AU  - Deckert J
AU  - Walther S
AU  - Unterecker S
AU  - Scherf-Clavel M
PY  - 2026
JO  - Pharmacopsychiatry
DO  - 10.1055/a-2812-9208
UR  - https://doi.org/10.1055/a-2812-9208
ER  - 

APA

GN, Z., B, W., J, D., S, W., S, U., & M, S. (2026). Serum Concentration-Dependent Inhibition of CYP2D6 by Bupropion and Doxepin: Implications for Venlafaxine and Risperidone Metabolism.. Pharmacopsychiatry. https://doi.org/10.1055/a-2812-9208

Source records